Fumarate Hydratase-Deficient Uterine Leiomyomas: Germline Genetic Findings and Clinical Follow-Up in a Single-Center Cohort

Background: Fumarate hydratase (FH)-deficient uterine leiomyomas are rare tumors that may be associated with germline FH variants and FH tumor predisposition syndrome. This study aimed to evaluate the clinical characteristics, germline genetic findings, and follow-up outcomes of patients with FH-deficient uterine leiomyomas, and to determine the frequency of germline pathogenic/likely pathogenic (P/LP) FH variants. Methods: This ambispective single-center cohort study included 19 patients diagnosed with FH-deficient uterine leiomyomas at a center between February 2021 and February 2026. Clinical characteristics, surgical data, FH and S-(2-succino) cysteine (2SC) immunohistochemical findings, germline FH analyses, renal imaging, dermatologic evaluation, and follow-up outcomes were reviewed. Results: Mean age was 44.9 ± 7.2 years, and the median largest leiomyoma diameter was 6.5 cm. Loss of FH expression was observed in 17/19 cases, while diffuse 2SC positivity was present in all cases. Among 17 patients who underwent germline testing, two (11.8%) harbored P/LP FH variants, [c.434C>G, p.(Ser145Ter) and c.1256C>G, p.(Ser419Ter)], and one (5.9%) had a variant of uncertain significance (VUS) [c.1090G>A, p.(Gly364Arg)]. Dermatologic evaluation was completed, with no cutaneous leiomyomas identified; no renal malignancy was detected on imaging in the two P/LP variant carriers. Among nine patients who underwent myomectomy, three developed recurrence; the patient carrying the likely pathogenic variant conceived after myomectomy. Conclusions: Identification of an FH-deficient uterine leiomyoma on pathologic examination is an important finding that should prompt evaluation for germline FH variants. These patients require integrated genetic, renal, dermatologic, and gynecologic follow-up. Obstetricians and gynecologists have an important role in initiating genetic evaluation and long-term surveillance after surgery.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2026-09-15
DOI
https://doi.org/10.3390/diagnostics16182985
Primary Topic
Uterine Myomas and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Fumarate Hydratase-Deficient Uterine Leiomyomas: Germline Genetic Findings and Clinical Follow-Up in a Single-Center Cohort

Abdülkadir Turgut, Melis Altug Inan, Ergül Demirçivi Bör, Elif Yılmaz Güleç et al.
Diagnostics
Uterine Myomas and Treatments
article

Fumarate Hydratase-Deficient Uterine Leiomyomas: Germline Genetic Findings and Clinical Follow-Up in a Single-Center Cohort

Abdülkadir Turgut, Melis Altug Inan, Ergül Demirçivi Bör, Elif Yılmaz Güleç, Canan Satır Özel, Hanne BULAT. Cim, Nisan Helin Dönmez, Begüm Sinem Kezer Cingoz, Emine Bolukbasi Karapinar
article en

Abstract

Background: Fumarate hydratase (FH)-deficient uterine leiomyomas are rare tumors that may be associated with germline FH variants and FH tumor predisposition syndrome. This study aimed to evaluate the clinical characteristics, germline genetic findings, and follow-up outcomes of patients with FH-deficient uterine leiomyomas, and to determine the frequency of germline pathogenic/likely pathogenic (P/LP) FH variants. Methods: This ambispective single-center cohort study included 19 patients diagnosed with FH-deficient uterine leiomyomas at a center between February 2021 and February 2026. Clinical characteristics, surgical data, FH and S-(2-succino) cysteine (2SC) immunohistochemical findings, germline FH analyses, renal imaging, dermatologic evaluation, and follow-up outcomes were reviewed. Results: Mean age was 44.9 ± 7.2 years, and the median largest leiomyoma diameter was 6.5 cm. Loss of FH expression was observed in 17/19 cases, while diffuse 2SC positivity was present in all cases. Among 17 patients who underwent germline testing, two (11.8%) harbored P/LP FH variants, [c.434C>G, p.(Ser145Ter) and c.1256C>G, p.(Ser419Ter)], and one (5.9%) had a variant of uncertain significance (VUS) [c.1090G>A, p.(Gly364Arg)]. Dermatologic evaluation was completed, with no cutaneous leiomyomas identified; no renal malignancy was detected on imaging in the two P/LP variant carriers. Among nine patients who underwent myomectomy, three developed recurrence; the patient carrying the likely pathogenic variant conceived after myomectomy. Conclusions: Identification of an FH-deficient uterine leiomyoma on pathologic examination is an important finding that should prompt evaluation for germline FH variants. These patients require integrated genetic, renal, dermatologic, and gynecologic follow-up. Obstetricians and gynecologists have an important role in initiating genetic evaluation and long-term surveillance after surgery.

DiagnosticsVol. 16(18)
İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi (TR), Istanbul Medeniyet University (TR)
Good health and well-being
Openalex Percentile: Top 8%
Uterine Myomas and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.